This presentation has some interesting info in relation to the approval of the Amylyx ALS/MND drug AMX0035 and the competition in general. There is a long way to go but compared to what is out there MPL is looking great IMO. A couple of extracts below:
Full Presentation:
https://www.fda.gov/media/161433/download
A lot to wade through but there is interesting info in there on biomarker baselines and the Functional Rating Scales, which may be of some use for some people for comparisons to MPL as more data emerges.
Ann: Results show MPL suppresses biomarkers associated with MND, page-156
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $86.55M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 19.5¢ | 18.5¢ | $330.4K | 1.741M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4071 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 24580 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| PAA (ASX) Chart |